Your browser is no longer supported. Please, upgrade your browser.
ESPR Esperion Therapeutics, Inc. daily Stock Chart
ESPR [NASD]
Esperion Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.72 Insider Own0.60% Shs Outstand29.49M Perf Week-12.84%
Market Cap907.11M Forward P/E- EPS next Y-7.20 Insider Trans154.81% Shs Float26.67M Perf Month-42.83%
Income-97.20M PEG- EPS next Q-3.33 Inst Own- Short Float23.28% Perf Quarter-48.75%
Sales148.40M P/S6.11 EPS this Y52.50% Inst Trans0.08% Short Ratio6.99 Perf Half Y-17.95%
Book/sh0.73 P/B42.14 EPS next Y0.30% ROA-38.30% Target Price89.27 Perf Year-26.55%
Cash/sh6.81 P/C4.52 EPS next 5Y28.30% ROE-98.90% 52W Range24.82 - 76.98 Perf YTD-48.42%
Dividend- P/FCF- EPS past 5Y-10.10% ROI-467.80% 52W High-60.04% Beta2.15
Dividend %- Quick Ratio3.20 Sales past 5Y- Gross Margin- 52W Low23.93% ATR4.46
Employees193 Current Ratio3.20 Sales Q/Q- Oper. Margin-62.70% RSI (14)36.29 Volatility10.74% 12.96%
OptionableYes Debt/Eq0.00 EPS Q/Q-1.10% Profit Margin-65.50% Rel Volume0.76 Prev Close32.97
ShortableYes LT Debt/Eq0.00 EarningsFeb 27 Payout- Avg Volume888.61K Price30.76
Recom1.70 SMA20-15.66% SMA50-38.75% SMA200-32.70% Volume679,196 Change-6.70%
Apr-01-20Resumed BofA/Merrill Buy $50
Mar-17-20Upgrade Citigroup Neutral → Buy
Feb-24-20Downgrade Northland Capital Outperform → Market Perform $60
Feb-14-20Downgrade Citigroup Buy → Neutral $82
Sep-16-19Upgrade Goldman Sell → Neutral $55 → $45
May-29-19Downgrade Goldman Neutral → Sell
May-06-19Upgrade BofA/Merrill Underperform → Neutral
Apr-26-19Upgrade Goldman Sell → Neutral $50
Mar-13-19Upgrade JP Morgan Underweight → Neutral $38 → $47
Jan-07-19Reiterated Needham Strong Buy $94 → $114
Dec-13-18Initiated Goldman Sell $45
Oct-29-18Upgrade Northland Capital Market Perform → Outperform
Oct-16-18Initiated BTIG Research Buy $82
Aug-17-18Upgrade Citigroup Neutral → Buy
Jul-11-18Downgrade Northland Capital Outperform → Market Perform
May-03-18Downgrade JP Morgan Neutral → Underweight $41
May-02-18Downgrade BofA/Merrill Buy → Underperform
Mar-27-18Reiterated Chardan Capital Markets Neutral $75 → $100
Feb-21-18Reiterated Needham Strong Buy $81 → $94
Jan-22-18Downgrade Citigroup Buy → Neutral
Apr-05-20 08:26AM  Revenue Downgrade: Here's What Analysts Forecast For Esperion Therapeutics, Inc. (NASDAQ:ESPR) Simply Wall St.
Mar-30-20 04:15PM  Esperion Announces Commercial Availability of the NEXLETOL (bempedoic acid) Tablet and Pledges a Conscientious Launch During Unprecedented Moment in Healthcare GlobeNewswire
Mar-28-20 11:30AM  Esperion Therapeutics (ESPR) Down 32.5% Since Last Earnings Report: Can It Rebound? Zacks
09:30AM  Esperion Announces Three Data Presentations of the NEXLETOL (bempedoic acid) Tablet and the NEXLIZET (bempedoic acid and ezetimibe) Tablet at the American College of Cardiologys 69th Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) GlobeNewswire
Mar-23-20 07:30AM  Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL (bempedoic acid) Tablet and Phase 2 Study Results of the NEXLIZET (bempedoic acid and ezetimibe) Tablet to be Presented at the American College of Cardiologys 69th Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) GlobeNewswire
Mar-18-20 07:30AM  Esperion Announces the Appointment of Alan Fuhrman to its Board of Directors GlobeNewswire +8.53%
Feb-28-20 04:15PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
08:12AM  Esperion (ESPR) Q4 Earnings and Revenues Beat Estimates Zacks
07:00AM  Esperion to Participate in Upcoming Investor Conferences GlobeNewswire
Feb-27-20 10:15AM  Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates Zacks -8.33%
07:35AM  The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy Benzinga
07:00AM  Esperion Provides Lipid Management Franchise Updates; Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
Feb-26-20 05:30PM  Esperion Announces FDA Approval of the NEXLIZET (bempedoic acid and ezetimibe) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine GlobeNewswire
Feb-21-20 04:38PM  Esperion Announces FDA Approval of NEXLETOL (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine GlobeNewswire -9.64%
04:27PM  Biotech Stock Crumbles Despite Esperion Nabbing A Key Drug Approval Investor's Business Daily
Feb-16-20 03:03PM  The Week Ahead In Biotech: Baudax Bio, Merck, Esperion Await FDA Decisions Benzinga
Feb-03-20 01:30PM  Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates Benzinga +5.68%
Jan-31-20 07:02AM  Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia GlobeNewswire
07:01AM  Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for Bempedoic Acid for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia GlobeNewswire
Jan-27-20 12:20PM  One Thing To Remember About The Esperion Therapeutics, Inc. (NASDAQ:ESPR) Share Price Simply Wall St.
Jan-07-20 07:30AM  Esperion to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-03-20 04:15PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Dec-12-19 11:59AM  Did Hedge Funds Drop The Ball On Esperion Therapeutics (ESPR) ? Insider Monkey
Dec-06-19 11:31AM  Esperion Therapeutics (ESPR) Up 25.1% Since Last Earnings Report: Can It Continue? Zacks +6.30%
Nov-28-19 07:09AM  Esperion's Promising Drugs Under Review, Funds a Concern Zacks
Nov-22-19 06:30PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +5.25%
Nov-19-19 09:13AM  Esperion Therapeutics (ESPR) Catches Eye: Stock Jumps 10% Zacks
Nov-17-19 03:05PM  Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions GlobeNewswire
Nov-12-19 11:05AM  Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results GlobeNewswire
Nov-10-19 07:56AM  President Timothy Mayleben Just Bought Shares In Esperion Therapeutics, Inc. (NASDAQ:ESPR) Simply Wall St.
Nov-09-19 09:26AM  Is Esperion Therapeutics's (NASDAQ:ESPR) Share Price Gain Of 215% Well Earned? Simply Wall St.
Nov-07-19 11:04AM  Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3 Zacks
07:30AM  Esperion to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-06-19 08:45AM  Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates Zacks -8.65%
07:30AM  Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results GlobeNewswire
Nov-04-19 07:30AM  Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions GlobeNewswire
Oct-29-19 07:30AM  Esperion to Report Third Quarter 2019 Financial Results November 6, 2019 GlobeNewswire
Oct-28-19 05:15PM  Should You Buy Esperion Therapeutics, Inc. (ESPR)? Insider Monkey
Oct-25-19 10:00AM  Bempedoic Acid Included in Top 10 Medical Innovations for 2020 List GlobeNewswire
Oct-04-19 08:34AM  Here's Why We're Not At All Concerned With Esperion Therapeutics's (NASDAQ:ESPR) Cash Burn Situation Simply Wall St.
Sep-09-19 10:57AM  7 Micro-Cap and Small-Cap Stocks That Insiders Are Buying InvestorPlace
Sep-07-19 09:30AM  Esperion Therapeutics (ESPR) Down 10.8% Since Last Earnings Report: Can It Rebound? Zacks
Sep-06-19 06:15PM  Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $259,125 of Shares GuruFocus.com
Aug-30-19 04:15PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
10:26AM  Esperion's Bempedoic Acid Succeeds in Phase II Diabetes Study Zacks
Aug-29-19 07:30AM  Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 Diabetes GlobeNewswire
Aug-26-19 11:05AM  Esperion's Drugs in Review Hold Potential, Funds a Concern Zacks
Aug-20-19 11:15AM  Does Market Volatility Impact Esperion Therapeutics, Inc.'s (NASDAQ:ESPR) Share Price? Simply Wall St.
Aug-09-19 08:06AM  Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat Zacks
Aug-08-19 09:15AM  Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:30AM  Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter Financial Results GlobeNewswire
Aug-06-19 04:15PM  Esperion to Present at the BTIG Biotechnology Conference GlobeNewswire
Aug-02-19 07:15PM  Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $197,800 of Shares GuruFocus.com
Jul-31-19 01:48PM  Steven Cohen Charges Into Chiasma GuruFocus.com
Jul-30-19 04:15PM  Esperion to Report Second Quarter 2019 Financial Results August 8, 2019 GlobeNewswire
03:16PM  A Firm's First Profit Can Mean Big Returns for Investors Zacks
Jul-29-19 08:08AM  3 Biotech Stocks Corporate Insiders are Buying TipRanks
Jul-07-19 07:10PM  Weekly CEO Buys Highlight GuruFocus.com
Jul-05-19 12:25PM  Is Esperion Therapeutics, Inc. (ESPR) A Good Stock To Buy? Insider Monkey
Jun-26-19 04:10PM  Esperion and Oberland Capital Announce $200 Million Funding Agreement GlobeNewswire
Jun-19-19 10:40AM  Have Insiders Been Buying Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares This Year? Simply Wall St.
Jun-07-19 09:30AM  Esperion Therapeutics (ESPR) Down 5.6% Since Last Earnings Report: Can It Rebound? Zacks
May-30-19 04:15PM  Esperion Announces the Appointment of Tracy M. Woody to Board of Directors GlobeNewswire
May-29-19 04:23PM  Biotech Stocks Clobbered As Two Slammed With Sell Ratings Investor's Business Daily
May-28-19 07:00AM  Esperion to Participate in Upcoming Investor Conferences GlobeNewswire
May-27-19 06:00AM  Esperion Aims for the First Approved Non-Statin Cholesterol Reducer MoneyShow
May-10-19 08:00AM  Esperion to Participate in Upcoming Investor Conferences GlobeNewswire
May-09-19 06:00AM  Esperion Gets a Go-Ahead from the FDA MoneyShow
May-08-19 08:35AM  Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Surpass Estimates Zacks
07:25AM  Esperion Therapeutics: 1Q Earnings Snapshot Associated Press
07:00AM  Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter Financial Results GlobeNewswire
May-07-19 05:30AM  Esperion to Host Analyst and Investor Day Event on May 30 GlobeNewswire
May-06-19 04:15PM  A Single Rival Caused 2 Biopharma Stocks To Slip Here's Why Investor's Business Daily +11.56%
01:30PM  Here's Why Esperion Therapeutics Shares Rocketed 11.5% Higher Today Motley Fool
10:33AM  Small-Cap Biotech Esperion Surges On FDA Acceptance Of Cholesterol Drug Applications Benzinga
May-05-19 05:00PM  Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review GlobeNewswire
May-02-19 02:41PM  Heres What Hedge Funds Think About Esperion Therapeutics, Inc. (ESPR) Insider Monkey
Apr-24-19 02:12PM  Moore Kuehn Encourages Esperion Therapeutics, Inc. Investors to Contact Law Firm for Possible Claims Against Officers and Directors PR Newswire
Apr-07-19 10:45PM  Weekly CEO Buys Highlight GuruFocus.com
Apr-02-19 04:30PM  Esperion to Present at the Needham & Company 18th Annual Healthcare Conference GlobeNewswire +8.04%
Apr-01-19 07:15PM  Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $200,000 of Shares GuruFocus.com
04:15PM  Esperion Announces Publication in The Journal of the American Heart Association of Bempedoic Acid Study 3 Results GlobeNewswire
Mar-30-19 09:30AM  Esperion Therapeutics (ESPR) Down 12.9% Since Last Earnings Report: Can It Rebound? Zacks
Mar-21-19 07:15PM  Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $217,400 of Shares GuruFocus.com
Mar-18-19 09:20AM  Esperion Announces Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 Study 2 at the American College of Cardiology 2019 Scientific Sessions GlobeNewswire
Mar-14-19 09:15PM  Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $243,650 of Shares GuruFocus.com -8.47%
Mar-13-19 05:05PM  Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine GlobeNewswire +7.55%
Mar-12-19 07:19AM  Did You Miss Esperion Therapeuticss (NASDAQ:ESPR) Impressive 225% Share Price Gain? Simply Wall St.
Mar-05-19 08:25AM  New Research Coverage Highlights Advance Auto Parts, AxoGen, Encana, Federal Signal, Nelnet, and Esperion Therapeutics Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Mar-04-19 04:30PM  Esperion to Participate in Upcoming Investor Conferences GlobeNewswire
08:00AM  Esperion Announces Presentation of Bempedoic Acid Pivotal Phase 3 Study 2 Results in a Late-Breaking Clinical Trial Session at the American College of Cardiology 2019 Scientific Sessions GlobeNewswire
Mar-01-19 09:39AM  Esperion (ESPR) Reports Wider-Than-Expected Loss in Q4 Zacks
Feb-28-19 04:30PM  Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
07:00AM  Esperion Announces Submissions of Two NDAs and Official Completion of Two MAA Validations for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet GlobeNewswire
Feb-22-19 05:30PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +5.39%
Jan-29-19 08:45AM  Update in Lawsuit for Investors in NASDAQ: ESPR shares against Esperion Therapeutics, Inc. announced by Shareholders Foundation GlobeNewswire
Jan-11-19 09:16AM  For Esperion Therapeutics, 2019 Could Be a Big Year Motley Fool
Jan-07-19 07:15AM  Update: Lawsuit for Investors in shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) announced by Shareholders Foundation ACCESSWIRE
02:00AM  Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet PR Newswire
Jan-06-19 10:00AM  All the Pre-JPM News Healthcare Investors Need to Know Motley Fool
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination tablet, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MAYLEBEN TIMOTHY MPresident & CEOMar 11Buy43.002,500107,500111,998Mar 12 07:34 AM
MAYLEBEN TIMOTHY MPresident & CEOFeb 28Buy49.005,000245,000109,498Mar 02 06:16 AM
BIOTECH TARGET N V10% OwnerJan 23Buy52.1220,0001,042,3983,747,964Jan 27 12:51 PM
MAYLEBEN TIMOTHY MPresident & CEONov 06Buy36.985,000184,90083,663Nov 08 04:14 PM
BIOTECH TARGET N V10% OwnerNov 06Buy37.3075,0002,797,5603,727,964Nov 08 02:54 PM
MAYLEBEN TIMOTHY MPresident & CEOSep 06Buy35.252,50088,12578,663Sep 06 04:22 PM
MAYLEBEN TIMOTHY MPresident & CEOSep 04Buy34.205,000170,98276,163Sep 06 04:22 PM
BIOTECH TARGET N V10% OwnerSep 04Buy33.7880,0002,702,2083,652,964Sep 06 04:09 PM
MAYLEBEN TIMOTHY MPresident & CEOAug 01Buy39.565,000197,80071,163Aug 02 04:06 PM
BIOTECH TARGET N V10% OwnerJul 23Buy42.6550,0002,132,5653,572,964Jul 25 12:42 PM
MAYLEBEN TIMOTHY MPresident & CEOJun 28Buy46.005,000230,00066,163Jul 01 04:57 PM